Cerity Partners
ADCT icon

Cerity Partners’s ADC Therapeutics ADCT Stock Holding History

Cerity Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Buy
+27,144
New +$79.2K ﹤0.01% 3343
2025
Q2 		– Sell
-17,912
Closed -$25.3K – 2627
2025
Q1 		$25.3K Buy
+17,912
New +$30.4K ﹤0.01% 2440

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cerity Partners's ADCT Position: Q2 2026 in Review

Cerity Partners opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 27,144 shares worth $29K. The stake represents ﹤0.01% of the portfolio and ranks #3343 among its holdings. This is a return to the name: Cerity Partners previously reported a position in ADCT as recently as Q1 2025.

Cerity Partners first reported a position in ADCT in Q1 2025 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Cerity Partners held 27,144 shares of ADC Therapeutics worth $29K as of Q2 2026.
  • ADC Therapeutics was a new Cerity Partners position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3343 holding.
  • Cerity Partners first reported a position in ADC Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.